Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Sep;72(3):583–588. doi: 10.1038/bjc.1995.377

Prostate-specific membrane antigen: evidence for the existence of a second related human gene.

J Leek 1, N Lench 1, B Maraj 1, A Bailey 1, I M Carr 1, S Andersen 1, J Cross 1, P Whelan 1, K A MacLennan 1, D M Meredith 1, et al.
PMCID: PMC2033874  PMID: 7669565

Abstract

Prostate-specific membrane antigen (PSM) is a glycoprotein recognised by the prostate-specific monoclonal antibody 7E11-C5, which was raised against the human prostatic carcinoma cell line LNCaP. A cDNA clone for PSM has been described. PSM is of clinical importance for a number of reasons. Radiolabelled antibody is being evaluated both as an imaging agent and as an immunotherapeutic in prostate cancer. Use of the PSM promoter has been advocated for gene therapy applications to drive prostate-specific gene expression. Although PSM is expressed in normal prostate as well as in primary and secondary prostatic carcinoma, different splice variants in malignant tissue afford the prospect of developing reverse transcription-polymerase chain reaction (RT-PCR)-based diagnostic screens for the presence of prostatic carcinoma cells in the circulation. We have undertaken characterisation of the gene for PSM in view of the protein's interesting characteristics. Unexpectedly, we have found that there are other sequences apparently related to PSM in the human genome and that PSM genomic clones map to two separate and distinct loci on human chromosome 11. Investigation of the function of putative PSM-related genes will be necessary to enable us to define fully the role of PSM itself in the development of prostatic carcinoma and in the clinical management of this malignancy.

Full text

PDF
583

Images in this article

585Figure 1
on p.585
585Figure 3
on p.585
585Figure 4
on p.585
586Figure 5
on p.586
586Figure 6
on p.586

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdel-Nabi H., Wright G. L., Gulfo J. V., Petrylak D. P., Neal C. E., Texter J. E., Begun F. P., Tyson I., Heal A., Mitchell E. Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol. 1992 Feb;10(1):45–54. [PubMed] [Google Scholar]
  2. Anand R., Riley J. H., Butler R., Smith J. C., Markham A. F. A 3.5 genome equivalent multi access YAC library: construction, characterisation, screening and storage. Nucleic Acids Res. 1990 Apr 25;18(8):1951–1956. doi: 10.1093/nar/18.8.1951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chiarodo A. National Cancer Institute roundtable on prostate cancer: future research directions. Cancer Res. 1991 May 1;51(9):2498–2505. [PubMed] [Google Scholar]
  4. Coffey D. S. Prostate cancer. An overview of an increasing dilemma. Cancer. 1993 Feb 1;71(3 Suppl):880–886. doi: 10.1002/1097-0142(19930201)71:3+<880::aid-cncr2820711403>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  5. Henttu P., Liao S. S., Vihko P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology. 1992 Feb;130(2):766–772. doi: 10.1210/endo.130.2.1370795. [DOI] [PubMed] [Google Scholar]
  6. Horoszewicz J. S., Kawinski E., Murphy G. P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987 Sep-Oct;7(5B):927–935. [PubMed] [Google Scholar]
  7. Horoszewicz J. S., Leong S. S., Kawinski E., Karr J. P., Rosenthal H., Chu T. M., Mirand E. A., Murphy G. P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983 Apr;43(4):1809–1818. [PubMed] [Google Scholar]
  8. Isaacs W. B., Carter B. S. Genetic changes associated with prostate cancer in humans. Cancer Surv. 1991;11:15–24. [PubMed] [Google Scholar]
  9. Israeli R. S., Powell C. T., Corr J. G., Fair W. R., Heston W. D. Expression of the prostate-specific membrane antigen. Cancer Res. 1994 Apr 1;54(7):1807–1811. [PubMed] [Google Scholar]
  10. Israeli R. S., Powell C. T., Fair W. R., Heston W. D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993 Jan 15;53(2):227–230. [PubMed] [Google Scholar]
  11. Kaighn M. E., Narayan K. S., Ohnuki Y., Lechner J. F., Jones L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979 Jul;17(1):16–23. [PubMed] [Google Scholar]
  12. Kao F. T., Jones C., Puck T. T. Genetics of somatic mammalian cells: genetic, immunologic, and biochemical analysis with Chinese hamster cell hybrids containing selected human chromosomes. Proc Natl Acad Sci U S A. 1976 Jan;73(1):193–197. doi: 10.1073/pnas.73.1.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Keer H. N., Kozlowski J. M., Tsai Y. C., Lee C., McEwan R. N., Grayhack J. T. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol. 1990 Feb;143(2):381–385. doi: 10.1016/s0022-5347(17)39970-6. [DOI] [PubMed] [Google Scholar]
  14. Koch J., Fischer H., Askholm H., Hindkjaer J., Pedersen S., Kølvraa S., Bolund L. Identification of a supernumerary der(18) chromosome by a rational strategy for the cytogenetic typing of small marker chromosomes with chromosome-specific DNA probes. Clin Genet. 1993 Apr;43(4):200–203. doi: 10.1111/j.1399-0004.1993.tb04448.x. [DOI] [PubMed] [Google Scholar]
  15. Landegent J. E., Jansen in de Wal N., Dirks R. W., Baao F., van der Ploeg M. Use of whole cosmid cloned genomic sequences for chromosomal localization by non-radioactive in situ hybridization. Hum Genet. 1987 Dec;77(4):366–370. doi: 10.1007/BF00291428. [DOI] [PubMed] [Google Scholar]
  16. Long A. A., Komminoth P., Lee E., Wolfe H. J. Comparison of indirect and direct in-situ polymerase chain reaction in cell preparations and tissue sections. Detection of viral DNA, gene rearrangements and chromosomal translocations. Histochemistry. 1993 Feb;99(2):151–162. doi: 10.1007/BF00571876. [DOI] [PubMed] [Google Scholar]
  17. Lopes A. D., Davis W. L., Rosenstraus M. J., Uveges A. J., Gilman S. C. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res. 1990 Oct 1;50(19):6423–6429. [PubMed] [Google Scholar]
  18. Parks G. D., Lamb R. A. Topology of eukaryotic type II membrane proteins: importance of N-terminal positively charged residues flanking the hydrophobic domain. Cell. 1991 Feb 22;64(4):777–787. doi: 10.1016/0092-8674(91)90507-u. [DOI] [PubMed] [Google Scholar]
  19. Pinkel D., Straume T., Gray J. W. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci U S A. 1986 May;83(9):2934–2938. doi: 10.1073/pnas.83.9.2934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rochon Y. P., Horoszewicz J. S., Boynton A. L., Holmes E. H., Barren R. J., 3rd, Erickson S. J., Kenny G. M., Murphy G. P. Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate. 1994 Oct;25(4):219–223. doi: 10.1002/pros.2990250408. [DOI] [PubMed] [Google Scholar]
  21. Rossi M. C., Zetter B. R. Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6197–6201. doi: 10.1073/pnas.89.13.6197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stone K. R., Mickey D. D., Wunderli H., Mickey G. H., Paulson D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978 Mar 15;21(3):274–281. doi: 10.1002/ijc.2910210305. [DOI] [PubMed] [Google Scholar]
  23. Wynant G. E., Murphy G. P., Horoszewicz J. S., Neal C. E., Collier B. D., Mitchell E., Purnell G., Tyson I., Heal A., Abdel-Nabi H. Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate. 1991;18(3):229–241. doi: 10.1002/pros.2990180305. [DOI] [PubMed] [Google Scholar]
  24. Yan G., Fukabori Y., McBride G., Nikolaropolous S., McKeehan W. L. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol. 1993 Aug;13(8):4513–4522. doi: 10.1128/mcb.13.8.4513. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES